On July 29, 2022 Avecho (ASX:AVE) reported that it has published its Quarterly Activities Report and 4C Quarterly Cash Flow Report, for the period ended 30 June 2022 (Press release, Phosphagenics, JUL 29, 2022, View Source [SID1234617118])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Key highlights from this period include:

Essential preparation underway for the commencement of Phase III CBD soft-gel program;
High profile exposure for Phase II data trialling the effectiveness of cannabinoids for treating arthritis of the hand, in top tier media and as part of the International Cannabis Research Society (ICRS) Conference in Galway;
Promising business development and partnership discussions ongoing for cannabinoid and broader portfolio of human health products;
Receipt of $1,007,990.22 under the Australian Government’s R&D Tax Incentive Scheme.
Avecho’s cash balance on 30 June was $3.13m.

On July 29, 2022 Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, reported it will host a conference call to discuss the second quarter 2022 financial results and provide a corporate update on Thursday, August 11, 2022 at 8:30 a.m. Eastern/5:30 a.m. Pacific (Press release, Spectrum Pharmaceuticals, JUL 29, 2022, View Source [SID1234617139]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call and Webcast:

Thursday, August 11, 2022 @ 8:30 a.m. Eastern/5:30 a.m. Pacific

To access the live call by phone, please go to this link (registration link), and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time.

A live webcast of the call will be available online in the Investor Relations section of the company’s website at View Source and will be archived there shortly after the live event.

On July 29, 2022 Orano reported its 2022 half-year results (Presentation, Orano, JUL 29, 2022, View Source;2022-half-year-results—download.pdf?sfvrsn=b561a0cd_4 [SID1234619153]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On July 29, 2022 AimedBio and GC cell reported to have signed a co-development agreement for a CAR-NK cell therapy drug.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The contract aims to derive candidates for CAR-NK drugs using AimedBio’s ‘AMB015’ antibodies that bind to cancer-specific proteins.

Through this collaboration, AimedBio hopes to expand their antibody-based therapeutics development area from ADCs to cell therapy.

(Press release, AimedBio, JUL 29, 2022, View Source;s_keyword=&s_where=&start=20 [SID1234656923])

On July 29, 2022 Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) reported that it will report its financial results for the second quarter of 2022, on Thursday, August 4, 2022, before the U.S. financial markets open (Press release, Concert Pharmaceuticals, JUL 29, 2022, View Source [SID1234617140]). The Company will host a conference call and webcast at 8:30 a.m. ET to discuss its second quarter 2022 financial results and provide a business update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Please note that there is a new system to access the live call in order to ask questions. To join the live call, please register here. A dial in and unique PIN will be provided to join the call.

An audio-only webcast of the call may be accessed in the Investors section of the Company’s website at www.concertpharma.com. A replay of the webcast will be available on Concert’s website for three months.